| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
CA2: COST COMPARISONS BETWEEN HOSPITALS IN DIFFERENT COUNTRIES BY MEANS OF A RESOURCE USE INDEX
|
Neymark, N
|
|
1999
|
2 |
5 |
p. 360-
1 p.
|
artikel
|
| 2 |
CA3: ESTIMATING SURVIVAL GAIN FOR COST-EFFECTIVENESS ANALYSIS: THE EXAMPLE OF EARLY HORMONAL TREATMENT IN LOCALLY ADVANCED PROSTATE CANCER
|
Neymark, N
|
|
1999
|
2 |
5 |
p. 360-361
2 p.
|
artikel
|
| 3 |
CA4: METASTATIC BREAST CANCER PATIENTS TREATED WITH DOCETAXEL
|
Burrell, A
|
|
1999
|
2 |
5 |
p. 361-
1 p.
|
artikel
|
| 4 |
CA1: PROSPECTIVE ECONOMIC EVALUATION OF ANTIBIOTIC PROPHYLAXIS IN SMALL CELL LUNG CANCER (SCLC) PATIENTS RECEIVING CHEMO THERAPY
|
Caleo, S
|
|
1999
|
2 |
5 |
p. 359-360
2 p.
|
artikel
|
| 5 |
CA5: QUALITY OF LIFE IN A BREAST CANCER POPULATION UNDERGOING ADJUVANT TREATMENT
|
Nichol, MB
|
|
1999
|
2 |
5 |
p. 361-
1 p.
|
artikel
|
| 6 |
CN2: AN ECONOMIC COMPARISON OF OLANZAPINE VERSUS HALOPERIDOL IN THE TREATMENT OF SCHIZOPHRENIA IN FRANCE
|
Gregor, KJ
|
|
1999
|
2 |
5 |
p. 353-354
2 p.
|
artikel
|
| 7 |
CN3: COST-EFFECTIVENESS OF RT-PA IN TREATMENT OF ACUTE ISCHAEMIC STROKE IN UK
|
Chambers, M
|
|
1999
|
2 |
5 |
p. 354-
1 p.
|
artikel
|
| 8 |
CN1: COSTS OF DEMENTIA IN GERMANY—AN ANALYSIS OF 7490 HEALTH INSURANCE FILES
|
Schwarz, UI
|
|
1999
|
2 |
5 |
p. 353-
1 p.
|
artikel
|
| 9 |
CN4: ECONOMIC APPROACH FOR ASSESSING THE OVERALL COST OF MANAGING ISCHEMIC EVENTS (MYOCARDIAL INFARCTION STROKE) IN ATHEROTHROMBOTIC PATIENTS: A EUROPEAN OVERVIEW
|
Levy, E
|
|
1999
|
2 |
5 |
p. 354-355
2 p.
|
artikel
|
| 10 |
CN6: EFFECTIVENESS OF PHARMACOLOGICAL TREATMENT OF HYPERTENSION UNDER EVERYDAY CIRCUMSTANCES WITH REGARD TO THE REDUCTION OF STROKE INCIDENCE
|
Klungel, OH
|
|
1999
|
2 |
5 |
p. 355-356
2 p.
|
artikel
|
| 11 |
CN8: PRODUCTIVITY COST MEASUREMENT: EMPIRICAL ANALYSIS OF QALY, HUMAN CAPITAL AND FRICTION COST METHODOLOGIES
|
Rothermich, EA
|
|
1999
|
2 |
5 |
p. 356-
1 p.
|
artikel
|
| 12 |
CN7: REDUCING ANTICHOLINERGIC ANTIDEPRESSANT USE IN THE ELDERLY: A RANDOMIZED TRIAL OF GROUP VERSUS INDIVIDUAL “ACADEMIC DETAILING”
|
Van, Eijk MEC
|
|
1999
|
2 |
5 |
p. 356-
1 p.
|
artikel
|
| 13 |
CN5: THE COST OF INPATIENT TREATMENT OF SCHIZOPHRENIA: A STUDY OF TWO LEADING ATYPICAL ANTIPSYCHOTICS
|
Duchesne, I
|
|
1999
|
2 |
5 |
p. 355-
1 p.
|
artikel
|
| 14 |
Current Trends in the Use of Pharmacoeconomics and Outcomes Research in Europe
|
Drummond, Michael
|
|
1999
|
2 |
5 |
p. 323-332
10 p.
|
artikel
|
| 15 |
CV3: A COST COMPARISON STUDY OF AMLODIPINE AND ENALAPRIL AS TREATMENT FOR HYPERTENSION IN THE UNITED STATES
|
Doyle, J
|
|
1999
|
2 |
5 |
p. 351-
1 p.
|
artikel
|
| 16 |
CV7: AMLODIPINE REDUCES HOSPITALIZATION ASSOCIATED WITH TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH CLINICAL CORONARY ARTERY DISEASE
|
Chen, G
|
|
1999
|
2 |
5 |
p. 352-353
2 p.
|
artikel
|
| 17 |
CV2: AN ECONOMIC ASSESSMENT OF DALTEPARIN VERSUS WARFARIN IN TOTAL HIP REPLACEMENT
|
Pleil, A
|
|
1999
|
2 |
5 |
p. 350-351
2 p.
|
artikel
|
| 18 |
CV6: COST-EFFECTIVENESS OF STATINS: MOVING BEYOND THE PRIMARY AND SECONDARY PREVENTION DISTINCTION
|
Caro, J
|
|
1999
|
2 |
5 |
p. 352-
1 p.
|
artikel
|
| 19 |
CV8: DETERMINANTS OF DISCONTINUATION OF NEW COURSES OF ANTIHYPERTENSIVE MEDICATIONS
|
Gregoire, JP
|
|
1999
|
2 |
5 |
p. 353-
1 p.
|
artikel
|
| 20 |
CV1: LONG TERM COMPLIANCE WITH ANTIHYPERTENSIVE DRUG THERAPY IN A MANAGED CARE ORGANIZATION
|
Simons, R
|
|
1999
|
2 |
5 |
p. 350-
1 p.
|
artikel
|
| 21 |
CV5: SIMULATED LIFETIME COSTS TO NATIONAL HEALTH SERVICE (NHS) OF BIOLOGICAL AND MECHANICAL HEART VALVE REPLACEMENT IN YOUNGER VERSUS OLDER PATIENTS
|
Griffiths, R
|
|
1999
|
2 |
5 |
p. 351-352
2 p.
|
artikel
|
| 22 |
CV4: THE COST OF HYPERTENSION AND ITS CORRELATES IN EMILIA ROMAGNA REGION (ITALY): RESULTS FROM THE GREAT STUDY
|
Ambrosioni, E
|
|
1999
|
2 |
5 |
p. 351-
1 p.
|
artikel
|
| 23 |
ED2: COST-EFFECTIVENESS OF ACROMEGALY TREATMENTS
|
Wilson, LS
|
|
1999
|
2 |
5 |
p. 369-
1 p.
|
artikel
|
| 24 |
ED1: COST-EFFECTIVENESS OF INTENSIVE METFORMIN VERSUS CONVENTIONAL THERAPY FOR OBESE PATIENTS WITH TYPE 2 DIABETES
|
Palmer, AJ
|
|
1999
|
2 |
5 |
p. 369-
1 p.
|
artikel
|
| 25 |
ED3: DEALING WITH CO-MORBIDITY AND RARE COMPLICATIONS IN A DIABETES TYPE 2 COST OF ILLNESS STUDY
|
Spannheimer, A
|
|
1999
|
2 |
5 |
p. 370-
1 p.
|
artikel
|
| 26 |
ED4: QUALITY OF LIFE AND USE OF HEALTHCARE RESOURCES IN GROWTH HORMONE-DEFICIENT ADULTS AFTER GROWTH HORMONE REPLACEMENT THERAPY
|
Hernberg-Ståhl, E
|
|
1999
|
2 |
5 |
p. 370-
1 p.
|
artikel
|
| 27 |
GI2: COST-EFFECTIVENESS ANALYSIS OF HIGH DOSE IV OMEPRAZOLE INFUSION AS ADJUVANT THERAPY TO ENDOSCOPIC HAEMOSTASIS FOR BLEEDING PEPTIC ULCERS
|
Lee, KKC
|
|
1999
|
2 |
5 |
p. 366-
1 p.
|
artikel
|
| 28 |
GI1: COST-EFFECTIVENESS OF THE COMBINATION OF MISOPROSTOL WITH DICLOFENAC IN THE TAYSIDE POPULATION
|
Morant, S
|
|
1999
|
2 |
5 |
p. 365-366
2 p.
|
artikel
|
| 29 |
GI3: EVALUATION OF PHARMACISTS' INTERVENTIONS ON PRESCRIBING ERRORS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: COSTS SAVINGS AND CLINICAL EFFECTS
|
Cousin, C
|
|
1999
|
2 |
5 |
p. 366-367
2 p.
|
artikel
|
| 30 |
GI4: PREDICTORS OF SAMPLE INCLUSION FOLLOWING THE APPLICATION OF CONTINUOUS ELIGIBILITY REQUIREMENTS IN SUBJECTS RECEIVING COLONOSCOPIES
|
Bramley, T
|
|
1999
|
2 |
5 |
p. 367-
1 p.
|
artikel
|
| 31 |
IR7: A SYSTEMATIC REVIEW OF SYSTEMIC AND TOPICAL ANTIMICROBIAL AGENTS USED IN THE PREVENTION AND TREATMENT OF CHRONIC WOUNDS
|
O'Meara, S
|
|
1999
|
2 |
5 |
p. 359-
1 p.
|
artikel
|
| 32 |
IR4: BUDESONIDE GAVE LOWER HEALTH CARE COSTS IN ASTHMA TREATMENT THAN FLUTICASONE PROPIONATE
|
Ericsson, Å
|
|
1999
|
2 |
5 |
p. 357-358
2 p.
|
artikel
|
| 33 |
IR8: COST-EFFECTIVENESS OF COMBINED HEPATITIS A AND B VACCINATION AND HEPATITIS B MONOVACCINATION IN SWITZERLAND AND AUSTRIA
|
Schneller, P
|
|
1999
|
2 |
5 |
p. 359-
1 p.
|
artikel
|
| 34 |
IR3: COST OF NOSOCOMIAL PNEUMONIA IN A LARGE TEACHING HOSPITAL
|
Dietrich, ES
|
|
1999
|
2 |
5 |
p. 357-
1 p.
|
artikel
|
| 35 |
IR5: DECISION ANALYSIS OF ACUTE TONSILLOPHARYNGITIS MANAGEMENT IN RUSSIAN CHILDREN
|
Stratchounski, L
|
|
1999
|
2 |
5 |
p. 358-
1 p.
|
artikel
|
| 36 |
IR6: DEVELOPMENT AND PRELIMINARY RESULTS OF THE HEALTH AND ECONOMIC CONSEQUENCES OF SMOKING MODEL
|
Orme, M
|
|
1999
|
2 |
5 |
p. 358-359
2 p.
|
artikel
|
| 37 |
IR2: THE COSTS OF THE INADEQUATE USE OF ANTIBIOTICS
|
Rovira, J
|
|
1999
|
2 |
5 |
p. 357-
1 p.
|
artikel
|
| 38 |
IR1: THE HEALTH ECONOMICS OF RECLASSIFICATION OF DRUGS FROM PRESCRIPTION ONLY MEDICINES TO PHARMACY STATUS
|
Rowlands, S
|
|
1999
|
2 |
5 |
p. 356-357
2 p.
|
artikel
|
| 39 |
PCA6: COST OF POSTMENOPAUSAL BREAST CANCER IN BELGIUM: AN INCIDENCE BASED APPROACH
|
Annemans, L
|
|
1999
|
2 |
5 |
p. 384-
1 p.
|
artikel
|
| 40 |
PCA5: EVALUATION OF POTENTIAL DRUG-INDUCED CHANGES IN HEALTH CARE UTILIZATION AND ATTENDANT COSTS: MODELS, DATABASE, AND EXAMPLES
|
Farquhar, I
|
|
1999
|
2 |
5 |
p. 383-
1 p.
|
artikel
|
| 41 |
PCA2: IRINOTECAN IN FIRST LINE TREATMENT OF METASTATIC COLORECTAL CANCER: IMPROVED SURVIVAL AND COST EFFECTIVENESS COMPARED WITH INFUSIONAL 5-FLUOROURACIL
|
Jackson, DL
|
|
1999
|
2 |
5 |
p. 382-
1 p.
|
artikel
|
| 42 |
PCA1: PHARMACOECONOMIC EVALUATION OF FILGRASTIM (r-metHuG-CSF) TREATMENT IN AUTOLOGOUS BONE MARROW TRANSPLANTATION
|
Privitera, G
|
|
1999
|
2 |
5 |
p. 382-
1 p.
|
artikel
|
| 43 |
PCA4: TRANSLATION OF THE QOL-RTI H&N QUESTIONNAIRE FOR ASSESSMENT OF HEALTH RELATED QUALITY OF LIFE IN PATIENTS UNDERGOING RADIATION THERAPY FOR HEAD AND NECK CANCER
|
Johnson, DJ
|
|
1999
|
2 |
5 |
p. 383-
1 p.
|
artikel
|
| 44 |
PCA3: TREATMENT PATHWAYS, RESOURCE USE AND COSTS IN THE MANAGEMENT OF SMALL CELL LUNG CANCER
|
Oliver, E
|
|
1999
|
2 |
5 |
p. 382-383
2 p.
|
artikel
|
| 45 |
PCN4: A COMPARISON OF ADULT MIGRAINE TREATMENT REGIMENS IN A MANAGED CARE POPULATION
|
Eaddy, M
|
|
1999
|
2 |
5 |
p. 385-
1 p.
|
artikel
|
| 46 |
PCN10: A CROSS-SECTIONAL ANALYSIS OF HEALTH CARE COST OF SSRI USERS
|
Goodman, M
|
|
1999
|
2 |
5 |
p. 387-388
2 p.
|
artikel
|
| 47 |
PCN8: ANTIPSYCHOTIC DRUG USE AND HOSPITALISATION IN PATIENTS WITH SCHIZOPHRENIA
|
de Vries, CS
|
|
1999
|
2 |
5 |
p. 387-
1 p.
|
artikel
|
| 48 |
PCN3: COST ANALYSIS OF SCHIZOPHRENIA TREATMENT IN GERMANY: A COMPARISON OF OLANZAPINE, RISPERIDONE, AND HALOPERIDOL USING A CLINICAL DECISION MODEL
|
Spannheimer, A
|
|
1999
|
2 |
5 |
p. 385-
1 p.
|
artikel
|
| 49 |
PCN9: COST-EFFECTIVENESS ANALYSIS AND SOCIAL ASPECTS OF THE PALMITATE PIPOTIASINE OUTPATIENT TREATMENT IN SCHIZOPHRENIA
|
Gurovich, I
|
|
1999
|
2 |
5 |
p. 387-
1 p.
|
artikel
|
| 50 |
PCN1: DIRECT AND INDIRECT TREATMENT COMPARISONS OF SECOND-GENERATION ANTIPSYCHOTIC DRUGS
|
Sauriol, L
|
|
1999
|
2 |
5 |
p. 384-
1 p.
|
artikel
|
| 51 |
PCN2: DOSES OF OLANZPINE, RISPERIDONE, AND HALOPERIDOL IN CLINICAL PRACTICE: RESULTS OF A PROSPECTIVE PHARMACOEOPIDEMIOGICAL STUDY (EFESO)
|
Sacristán, JA
|
|
1999
|
2 |
5 |
p. 384-385
2 p.
|
artikel
|
| 52 |
PCN7: ECONOMIC ASPECTS OF AN INTERNATIONAL STUDY OF MAJOR DEPRESSIVE DISORDER IN PRIMARY CARE PATIENTS (THE LIDO STUDY)
|
Chisholm, D
|
|
1999
|
2 |
5 |
p. 386-
1 p.
|
artikel
|
| 53 |
PCN12: HEALTH ECONOMICS FOR N-OF-1 TRIALS
|
Qizilbash, N
|
|
1999
|
2 |
5 |
p. 388-
1 p.
|
artikel
|
| 54 |
PCN6: MODELLING THE LONG-TERM COST EFFECTIVENESS OF RILUZOLE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
|
Tavakoli, M
|
|
1999
|
2 |
5 |
p. 386-
1 p.
|
artikel
|
| 55 |
PCN5: THE USE OF INTERNATIONAL, DISEASE SPECIFIC, CROSS-SECTIONAL DATABASES FOR PHARMACOECONOMIC RESEARCH
|
Crawford, B
|
|
1999
|
2 |
5 |
p. 385-386
2 p.
|
artikel
|
| 56 |
PCN11: UK SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (UK-SCAP)—A PROSPECTIVE, OBSERVATIONAL STUDY OF THE TREATMENT AND OUTCOMES OF DRUG THERAPY FOR SCHZOPHRENIA IN A NATURALISTIC SETTING
|
McKendrick, J
|
|
1999
|
2 |
5 |
p. 388-
1 p.
|
artikel
|
| 57 |
PCV7: AN ECONOMIC ANALYSIS OF TELMISARTAN (MICARDIS®) TREATMENT FOR PEOPLE WITH MILD TO MODERATE HYPERTENSION IN THE UK
|
Backhouse, M
|
|
1999
|
2 |
5 |
p. 391-
1 p.
|
artikel
|
| 58 |
PCV4: COST ANALYSIS OF AMLODIPINE VERSUS FELODIPINE ER IN THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION
|
Berliner, E
|
|
1999
|
2 |
5 |
p. 390-
1 p.
|
artikel
|
| 59 |
PCV9: COST-COMPARISON ANALYSIS OF HOME MONITORING AND AMBULANT MONITORING OF ORAL ANTICOAGULATION IN SWITZERLAND
|
Neeser, K
|
|
1999
|
2 |
5 |
p. 392-
1 p.
|
artikel
|
| 60 |
PCV6: COST OF SECOND LINE PHARMACEUTICAL MANAGEMENT OF ATRIAL FIBRILLATION IN FRANCE
|
Annemans, L
|
|
1999
|
2 |
5 |
p. 391-
1 p.
|
artikel
|
| 61 |
PCV3: COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER IN THE UNITED STATES
|
Bhattacharyya, SK
|
|
1999
|
2 |
5 |
p. 389-390
2 p.
|
artikel
|
| 62 |
PCV1: DIRECT COSTS OF MAINTAINING NORMAL SINUS RHYTHM IN PATIENTS WITH ATRIAL FIBRILLATION IN THE NETHERLANDS: A MODELING APPROACH
|
Bhattacharyya, SK
|
|
1999
|
2 |
5 |
p. 388-389
2 p.
|
artikel
|
| 63 |
PCV12: ECONOMIC EVALUATION OF ACE INHIBITORS IN SPAIN
|
Asensio, J
|
|
1999
|
2 |
5 |
p. 393-
1 p.
|
artikel
|
| 64 |
PCV8: HOSPITALIZATION PROFILE OF PATIENTS WITH ATRIAL FIBRILLATION OR FLUTTER: AN ADMINISTRATIVE DATABASE ANALYSIS
|
Bhattacharyya, SK
|
|
1999
|
2 |
5 |
p. 391-392
2 p.
|
artikel
|
| 65 |
PCV5: MANAGEMENT OF PERIPHERAL ARTERIAL DISEASE (PAD) PATIENTS: MODELLING THE RISK OF ISCHEMIC EVENTS AND THEIR ECONOMIC CONSEQUENCES
|
Levy, E
|
|
1999
|
2 |
5 |
p. 390-391
2 p.
|
artikel
|
| 66 |
PCV10: PREDICTORS OF ADHERENCE TO LIPID-LOWERING THERAPY
|
de Vries, CS
|
|
1999
|
2 |
5 |
p. 392-393
2 p.
|
artikel
|
| 67 |
PCV11: STUDY OF HEALTH CARE RESOURCE USE FOR ELDERLY PATIENTS WITH MILD AND MODERATE ARTERIAL HYPERTENSION
|
Geltzer, B
|
|
1999
|
2 |
5 |
p. 393-
1 p.
|
artikel
|
| 68 |
PCV2: THE COST-EFFECTIVENESS OF CHOLESTEROL LOWERING TREATMENT IN THE PRIMARY PREVENTION OF CORONARY HEART DISEASE: THE CASE OF A COMPREHENSIVE DIETARY INTERVENTION PROGRAM
|
Long, K
|
|
1999
|
2 |
5 |
p. 389-
1 p.
|
artikel
|
| 69 |
PEN8: CODE-2* UK: THE CURRENT COSTS OF TYPE-2 DIABETES IN THE UK
|
Bottomley, J
|
|
1999
|
2 |
5 |
p. 396-
1 p.
|
artikel
|
| 70 |
PEN6: COSTS OF TREATING NAIVE PATIENTS WITH TYPE 2 DIABETES—A COMPARISON BETWEEN THE UNITED KINGDOM AND FRANCE
|
Pashos, CL
|
|
1999
|
2 |
5 |
p. 395-396
2 p.
|
artikel
|
| 71 |
PEN3: DEVELOPMENT OF AN ALGORITHM FOR ESTIMATING ASTHMA SEVERITY FROM AN ADMINISTRATIVE COST DATABASE
|
Leidy, NK
|
|
1999
|
2 |
5 |
p. 394-395
2 p.
|
artikel
|
| 72 |
PEN7: DIRECT COSTS OF DIABETES IN ITALY
|
Garattini, L
|
|
1999
|
2 |
5 |
p. 396-
1 p.
|
artikel
|
| 73 |
PEN4: MEASURING THE REAL ANNUAL DIRECT COSTS OF DIABETES TYPE 2 PATIENTS IN GERMANY
|
Goertz, A
|
|
1999
|
2 |
5 |
p. 395-
1 p.
|
artikel
|
| 74 |
PEN5: METHODOLOGICAL ASPECTS OF MULTI-COUNTRY COST OF ILLNESS STUDIES—1: DATA COLLECTION INSTRUMENT DESIGN
|
Kirsch, J
|
|
1999
|
2 |
5 |
p. 395-
1 p.
|
artikel
|
| 75 |
PEN2: METHODOLOGICAL ASPECTS OF MULTI COUNTRY COST OF ILLNESS STUDIES—2: INTERNET BASED DATA MANAGEMENT
|
Kirsch, J
|
|
1999
|
2 |
5 |
p. 394-
1 p.
|
artikel
|
| 76 |
PEN9: PHARMACODYNAMIC-PHARMACOECONOMIC (PD-PE) MODEL OF ASTHMA ANTI-INFLAMMATORY THERAPIES
|
Handley, DA
|
|
1999
|
2 |
5 |
p. 396-397
2 p.
|
artikel
|
| 77 |
PEN1: QUALITY-OF-LIFE-EVALUATION OF THE GERMAN S.A.T.-TRIAL - COMPARISON OF SF-36, EUROQOL, TIME-TRADE-OFF METHOD AND WILLINGNESS-TO-PAY
|
Wendland, G
|
|
1999
|
2 |
5 |
p. 393-394
2 p.
|
artikel
|
| 78 |
PG15: COST OF ILLNESS STUDIES MAY LARGELY UNDERESTIMATE THE COST OF DISEASES WITH UNMET MEDICAL NEED SUCH AS IRRITABLE BOWEL SYNDROME (IBS)
|
Volmer, T
|
|
1999
|
2 |
5 |
p. 399-
1 p.
|
artikel
|
| 79 |
PG14: COST OF ITALIAN DYSPEPTIC PATIENTS: A FEASIBILITY STUDY FROM THE DYSPEPSIA PROJECT
|
Triossi, O
|
|
1999
|
2 |
5 |
p. 398-
1 p.
|
artikel
|
| 80 |
PG12: DIAGNOSIS AND TREATMENT OF CONSTIPATION IN A MANAGED CARE POPULATION
|
Bramley, T
|
|
1999
|
2 |
5 |
p. 397-398
2 p.
|
artikel
|
| 81 |
PG13: DIFFERENTIAL COST OF USING NSAIDS IN A MEDICAID POPULATION
|
Dickson, WM
|
|
1999
|
2 |
5 |
p. 398-
1 p.
|
artikel
|
| 82 |
PGI1: EFFECTIVENESS OF OMEPRAZOLE, AMOXICILLIN, AND CLARITHROMYCIN IN ERADICATING HELICOBACTER PYLORI IN PATIENTS ON CHRONIC ACID SUPPRESSION FOR PEPTIC ULCER DISEASE OR ULCER-LIKE SYMPTOMS
|
Allison, J
|
|
1999
|
2 |
5 |
p. 397-
1 p.
|
artikel
|
| 83 |
Pharmacoeconomics in European Decision-Making
|
Nuijten, Mark JC
|
|
1999
|
2 |
5 |
p. 319-322
4 p.
|
artikel
|
| 84 |
PID2: ASSESSING THE DIRECT COST OF LYME DISEASE
|
Goodman, M
|
|
1999
|
2 |
5 |
p. 401-
1 p.
|
artikel
|
| 85 |
PID4: COST-EFFECTIVENESS OF PARTNER PHARMACOTHERAPY IN SCREENING FOR CHLAMYDIA TRACHOMATIS
|
Postma, MJ
|
|
1999
|
2 |
5 |
p. 402-
1 p.
|
artikel
|
| 86 |
PID1: ESTIMATES OF THE INDIRECT COSTS OF HIV AND AIDS IN THE UNITED KINGDOM
|
Mullins, CD
|
|
1999
|
2 |
5 |
p. 401-
1 p.
|
artikel
|
| 87 |
PID3: HOSPITALIZATION RATES AND ASSOCIATED COSTS FOR INFLUENZA IN A MANAGED CARE POPULATION
|
Eaddy, M
|
|
1999
|
2 |
5 |
p. 401-402
2 p.
|
artikel
|
| 88 |
PID5: RETROSPECTIVE STUDY COMPARING COST-EFFECTIVENESS OF NEWER AMPHOTERICIN B PREPARATIONS
|
Tsakalou, A
|
|
1999
|
2 |
5 |
p. 402-403
2 p.
|
artikel
|
| 89 |
PID6: TREATMENT OF ACUTE OTITIS MEDIA IN A MANAGED CARE POPULATION
|
McLaughlin, T
|
|
1999
|
2 |
5 |
p. 403-
1 p.
|
artikel
|
| 90 |
PMW4: A MICRO-COST ANALYSIS OF URINARY INCONTINENCE CARE IN LONG-TERM CARE FACILITIES
|
Hartzema, AG
|
|
1999
|
2 |
5 |
p. 400-401
2 p.
|
artikel
|
| 91 |
PMW1: COSTS OF TREATMENT WITH DOXAZOSIN VERSUS TAMSULOSIN IN MEN WITH BENIGN PROSTATIC HYPERPLASIA
|
Thompson, D
|
|
1999
|
2 |
5 |
p. 399-
1 p.
|
artikel
|
| 92 |
PMW3: ECONOMICAL ANALYSIS OF THE RESULTS OF PROSTATE CANCER SCREENING PROGRAM
|
Komarova, LE
|
|
1999
|
2 |
5 |
p. 400-
1 p.
|
artikel
|
| 93 |
PMW2: THE VALUATION OF ERECTILE DYSFUNCTION: CONVERTING CLINICAL OUTCOMES INTO UTILITIES
|
Stolk, EA
|
|
1999
|
2 |
5 |
p. 399-400
2 p.
|
artikel
|
| 94 |
PTH5: A COST-MINIMIZATION ANALYSIS OF IRON DEFICIENCY ANEMIA TREATMENT
|
Vorobiev, PA
|
|
1999
|
2 |
5 |
p. 405-
1 p.
|
artikel
|
| 95 |
PTH11: APPLYING DECISIONAL ANALYSIS TO METERED DOSE INHALER MONITORING AND EDUCATIONAL OUTCOMES
|
Sampson, JM
|
|
1999
|
2 |
5 |
p. 407-
1 p.
|
artikel
|
| 96 |
PTH4: ECONOMIC EVALUATION BY UK PHARMACEUTICAL AND MEDICAL DEVICE FIRMS: GENERAL TRENDS AND POLICY IMPLICATIONS
|
Cookson, R
|
|
1999
|
2 |
5 |
p. 404-405
2 p.
|
artikel
|
| 97 |
PTH10: EVALUATING PHARMACEUTICAL COSTS OF PATIENTS WITH CHRONIC LUNG DISEASE IN GERMAN IN- AND OUTPATIENTS SETTING
|
Hessel, F
|
|
1999
|
2 |
5 |
p. 407-
1 p.
|
artikel
|
| 98 |
PTH7: GLOBAL SCALE VERSUS GENERIC AND DISEASE-SPECIFIC INSTRUMENTS TO MEASURE THE HEALTH STATUS OF PATIENTS WITH ASTHMA
|
Hajiro, T
|
|
1999
|
2 |
5 |
p. 405-406
2 p.
|
artikel
|
| 99 |
PTH3: GUIDELINES FOR SUBMISSION OF REQUESTS FOR INCLUSION OF A PHARMACEUTICAL PRODUCT IN THE ISRAELI NATIONAL FORMULARY
|
Shani, S
|
|
1999
|
2 |
5 |
p. 404-
1 p.
|
artikel
|
| 100 |
PTH12: INTENSIVE CARE COSTS OF TREATING PEDIATRIC PATIENTS WITH ACUTE RESPIRATORY DISTRESS SYNDROME: HOW CAN THESE BE MEASURED?
|
Sauriol, L
|
|
1999
|
2 |
5 |
p. 407-408
2 p.
|
artikel
|
| 101 |
PTH2: MALIGNANT RETROPERITONEAL TUMOURS OF CHILDREN: FIRST RESEARCH OF QUALITY OF LIFE OF 278 SURVIVED PATIENTS
|
Zaeva, G
|
|
1999
|
2 |
5 |
p. 403-404
2 p.
|
artikel
|
| 102 |
PTH6: PATIENTS' PERCEPTIONS OF THE OUTCOMES OF TREATMENT WITH TOPICAL NSAIDS, RUBIFACIANTS AND ORAL PAIN REMEDIES. A PROSPECTIVE STUDY OF MEDICINES AVAILABLE THROUGH COMMUNITY PHARMACIES
|
McNaughton, D
|
|
1999
|
2 |
5 |
p. 405-
1 p.
|
artikel
|
| 103 |
PTH8: POTENTIAL COST SAVINGS ASSOCIATED WITH ASTHMA DRUG THERAPIES USING INTEGRATED DRUG AND MEDICAL CLAIMS DATA
|
Andrews, K
|
|
1999
|
2 |
5 |
p. 406-
1 p.
|
artikel
|
| 104 |
PTH9: RETROSPECTIVE OUTCOMES ANALYSIS OF THE EFFECTS OF ZAFIRLUKAST THERAPY IN THE MANAGEMENT OF PATIENTS WITH ASTHMA IN THE UNITED STATES
|
Silverman, S
|
|
1999
|
2 |
5 |
p. 406-407
2 p.
|
artikel
|
| 105 |
PTH13: THE APPLICATION OF PORTFOLIO MANAGEMENT TECHNIQUES TO PHARMACEUTICAL R&D PROJECT SELECTION AND COST-EFFECTIVENESS ANALYSIS
|
Tran, G
|
|
1999
|
2 |
5 |
p. 408-
1 p.
|
artikel
|
| 106 |
PTH1: USE OF ADMINISTRATIVE DATA FOR POST-MARKET SURVEILLANCE OF THE OUTCOME OF TOTAL HIP AND KNEE REPLACEMENTS
|
Silverman, B
|
|
1999
|
2 |
5 |
p. 403-
1 p.
|
artikel
|
| 107 |
QL3: ANTIPSYCHOTIC TREATMENT AND CHANGES IN HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA USING EQ-5D
|
Badia, X
|
|
1999
|
2 |
5 |
p. 362-363
2 p.
|
artikel
|
| 108 |
QL5: ASTHMA BOTHER PROFILE VERSUS AIRWAY QUESTIONNAIRE 20 AS SIMPLE MEASURES TO EVALUATE THE HEALTH STATUS IN ASTHMA
|
Nishimura, K
|
|
1999
|
2 |
5 |
p. 363-
1 p.
|
artikel
|
| 109 |
QL2: PSYCHOMETRIC EQUIVALENCE EVALUATION OF FIVE NON-WESTERN-LANGUAGE TRANSLATED VERSIONS OF THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY—GENERAL (FACT-G) VERSION 4
|
Eremenco, S
|
|
1999
|
2 |
5 |
p. 362-
1 p.
|
artikel
|
| 110 |
QL1: THE QUALITY OF LIFE OF ESSENTIAL HYPERTENSIVES IN AN ECONOMICALLY DISADVANTAGED COMMUNITY: PREDICTORS AND RELEVANCE TO MANAGEMENT COMPLIANCE
|
Golubev, SA
|
|
1999
|
2 |
5 |
p. 361-362
2 p.
|
artikel
|
| 111 |
QL4: USING RASCH MODELS TO IMPROVE THE EVALUATIVE-SCALE PROPERTIES OF THE WOMEN'S HEALTH QUESTIONNAIRE
|
Turner, R
|
|
1999
|
2 |
5 |
p. 363-
1 p.
|
artikel
|
| 112 |
SD2: GENERICS ONLY OR GENERICS AND EFFICIENT DRUGS?
|
Bendahan, G
|
|
1999
|
2 |
5 |
p. 368-
1 p.
|
artikel
|
| 113 |
SD4: QUALITY OF LIFE ASSESSMENT AS A NEW OUTCOME MEASURE IN CLINICAL PRACTICE
|
Pratheepawanit, N
|
|
1999
|
2 |
5 |
p. 368-369
2 p.
|
artikel
|
| 114 |
SD1: USING CONJOINT ANALYSIS TO ASSESS WOMEN'S PREFERENCES FOR MATERNITY CARE SERVICES DURING THE INTRAPARTUM STAGE
|
Ratcliffe, J
|
|
1999
|
2 |
5 |
p. 367-368
2 p.
|
artikel
|
| 115 |
SD3: USING ECONOMIC INFORMATION IN HOSPITAL FORMULARY DECISION-MAKING
|
Späth, HM
|
|
1999
|
2 |
5 |
p. 368-
1 p.
|
artikel
|
| 116 |
SR2: A PHARMACO-ECONOMIC CASE STUDY IN ANAESTHESIA, INCLUDING A RECENT RE-ANALYSIS USING BOOTSTRAP TECHNIQUES
|
McNamara, J
|
|
1999
|
2 |
5 |
p. 364-
1 p.
|
artikel
|
| 117 |
SR3: DEVELOPMENT AND VALIDATION OF THE QUALITY OF LIFE WITH MIGRAINE (QOLWM): A BRIEF MIGRAINE SURVEY
|
Cramer, JA
|
|
1999
|
2 |
5 |
p. 364-365
2 p.
|
artikel
|
| 118 |
SR4: LONGITUDINAL ASSESSMENT OF ASTHMA AND WORK OUTCOMES
|
Erickson, SR
|
|
1999
|
2 |
5 |
p. 365-
1 p.
|
artikel
|
| 119 |
SR5: MEDICAL EVENTS AND RESOURCE UTILISATION IN CANCER PAIN PATIENTS TREATED WITH STRONG OPIOIDS: AN ANALYSIS OF THE UK-GPRD DATABASE
|
Nuyts, GD
|
|
1999
|
2 |
5 |
p. 365-
1 p.
|
artikel
|
| 120 |
SR1: THE ECONOMIC IMPACT OF TOLTERODINE IN PORTUGAL
|
Dias, J
|
|
1999
|
2 |
5 |
p. 363-364
2 p.
|
artikel
|
| 121 |
The Influence of Case Mix, Site Selection, and Methods Biases on Costs of Hospitalization For Acute Exacerbations of Chronic Obstructive Airways Disease and Lower Respiratory Tract Infections
|
Davey, Peter G.
|
|
1999
|
2 |
5 |
p. 333-341
9 p.
|
artikel
|
| 122 |
The Norwegian Version of the Psoriasis Disability Index — A Validation and Reliability Study
|
Wahl, A.K.
|
|
1999
|
2 |
5 |
p. 342-349
8 p.
|
artikel
|
| 123 |
TPC4: AN ECONOMIC EVALUATION OF AMLODIPINE FOR THE TREATMENT OF NONISCHEMIC DILATED CARDIOMYOPATHY: THE PROSPECTIVE RANDOMIZED AMLODIPINE SURVIVAL EVALUATION (PRAISE)
|
Glick, HA
|
|
1999
|
2 |
5 |
p. 379-380
2 p.
|
artikel
|
| 124 |
TPC1: COST-EFFECTIVENESS ANALYSIS OF BUDESONIDE VERSUS DISODIUM CROMOGLYCATE THERAPY IN CHILDREN WITH MODERATE BRONCHIAL ASTHMA
|
Szende, A
|
|
1999
|
2 |
5 |
p. 378-
1 p.
|
artikel
|
| 125 |
TPC2: COST-MINIMIZATION ANALYSIS OF TWO TRIPLE REGIMENS FOR THE TREATMENT OF HELICOBACTER PYLORI-RELATED PEPTIC ULCER DISEASE
|
You, JH
|
|
1999
|
2 |
5 |
p. 378-379
2 p.
|
artikel
|
| 126 |
TPC3: COST OF AML TREATMENT IN BELGIUM: RESULTS OF A RANDOMIZED TRIAL WITH AND WITHOUT FILGRASTIM USE
|
Noens, L
|
|
1999
|
2 |
5 |
p. 379-
1 p.
|
artikel
|
| 127 |
TPE1: ASSESSMENT OF THE APPROPRIATENESS OF CLINICAL GUIDELINES FOR CONTINUATION TREATMENT IN MAJOR DEPRESSION FROM A HEALTH ECONOMIC PERSPECTIVE
|
Nuijten, MJC
|
|
1999
|
2 |
5 |
p. 374-
1 p.
|
artikel
|
| 128 |
TPE5: COST OF MANAGING BENIGN PROSTATE HYPERPLASIA IN BELGIUM
|
Annemans, L
|
|
1999
|
2 |
5 |
p. 376-
1 p.
|
artikel
|
| 129 |
TPE4: DEVELOPMENT OF A QUALITY ASSESSMENT CHECKLIST FOR THE APPRAISAL OF ECONOMIC MODELS: A CASE-STUDY IN OSTEOPOROSIS
|
Hege, U
|
|
1999
|
2 |
5 |
p. 375-376
2 p.
|
artikel
|
| 130 |
TPE3: ECONOMIC EVALUATION OF DIFFERENT STRATEGIES OF A VACCINATION AGAINST HEPATITIS A AND HEPATITIS B
|
Smala, A
|
|
1999
|
2 |
5 |
p. 375-
1 p.
|
artikel
|
| 131 |
TPE2: ECONOMIC EVALUATION OF ENOXAPARIN AS POST DISCHARGE PROPHYLAXIS FOR DEEP VEIN THROMBOSIS (DVT) IN ELECTIVE HIP SURGERY
|
Davies, LM
|
|
1999
|
2 |
5 |
p. 375-
1 p.
|
artikel
|
| 132 |
TPL3: BEST EVIDENCE IN PHARMACOECONOMICS
|
Mallarkey, G
|
|
1999
|
2 |
5 |
p. 381-
1 p.
|
artikel
|
| 133 |
TPL2: MULTINATIONAL ECONOMIC EVALUATIONS: A REVIEW OF PUBLISHED STUDIES, METHODOLOGICAL ISSUES AND PRACTICE
|
Pang, F
|
|
1999
|
2 |
5 |
p. 380-
1 p.
|
artikel
|
| 134 |
TPL1: STATE OF THE ART IN PHARMACOECONOMIC EVALUATION: A REVIEW OF METHODS AND PRACTICE
|
Pang, F
|
|
1999
|
2 |
5 |
p. 380-
1 p.
|
artikel
|
| 135 |
TPM5: BURDEN OF BRONCHIAL ASTHMA: FAMILY EXPENSES FOR CHILD'S DISEASE
|
Prosekova, E
|
|
1999
|
2 |
5 |
p. 378-
1 p.
|
artikel
|
| 136 |
TPM1: DIRECT AND INDIRECT COST OF MIGRAINE IN ITALY
|
Arpinelli, F
|
|
1999
|
2 |
5 |
p. 376-
1 p.
|
artikel
|
| 137 |
TPM2: ONE-YEAR REHOSPITALISATION RATE IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
|
Tavcar, R
|
|
1999
|
2 |
5 |
p. 377-
1 p.
|
artikel
|
| 138 |
TPM3: THE EFFECT OF OBSERVATION DURATION ON CLAIMS-BASED RISK ADJUSTMENT SCORES
|
Andrews, K
|
|
1999
|
2 |
5 |
p. 377-
1 p.
|
artikel
|
| 139 |
TPP2: EVALUATION OF A THERAPEUTIC INTERCHANGE PROGRAM FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION
|
Nichol, MB
|
|
1999
|
2 |
5 |
p. 373-
1 p.
|
artikel
|
| 140 |
TPP1: IMPLEMENTING A MODEL OF RISK SHARING OF PHARMACEUTICAL BENEFITS IN PRIMARY CARE
|
Gilabert, A
|
|
1999
|
2 |
5 |
p. 373-
1 p.
|
artikel
|
| 141 |
TPP3: PHARMACEUTICAL CARE AND HEALTH CARE UTILIZATION
|
Fischer, LR
|
|
1999
|
2 |
5 |
p. 373-374
2 p.
|
artikel
|
| 142 |
TPP4: POTENTIAL COST SAVINGS BY PRESCRIPTION OF THE CHEAPEST DRUGS AMONG THOSE WITH EQUAL CONTENT IN PRIMARY CARE
|
de Rey E, Alegre
|
|
1999
|
2 |
5 |
p. 374-
1 p.
|
artikel
|
| 143 |
TPQ4: A EUROPEAN EQ-5D VALUE SET. MYTH OR REALITY?
|
De Charro, F
|
|
1999
|
2 |
5 |
p. 372-
1 p.
|
artikel
|
| 144 |
TPQ2: A REVIEW OF AVAILABLE HEALTH-RELATED QUALITY OF LIFE (HRQL) REFERENCE VALUES IN THE MEDICAL LITERATURE
|
Keininger, DL
|
|
1999
|
2 |
5 |
p. 371-
1 p.
|
artikel
|
| 145 |
TPQ3: EUROPEAN GUIDANCE DOCUMENT FOR THE IMPROVEMENT OF THE INTEGRATION OF HEALTH-RELATED QUALITY OF LIFE (HRQL) ASSESSMENT IN THE DRUG REGULATORY PROCESS
|
Chassany, O
|
|
1999
|
2 |
5 |
p. 371-372
2 p.
|
artikel
|
| 146 |
TPQ5: MAPI RESEARCH INSTITUTE HEALTH-RELATED QUALITY OF LIFE OUTCOMES DATABASE (IQOD) PROJECT
|
Keininger, DL
|
|
1999
|
2 |
5 |
p. 372-
1 p.
|
artikel
|
| 147 |
TPQ1: THE EUROPEAN REGULATORY ISSUES ON QUALITY OF LIFE ASSESSMENT (ERIQA) PROJECT
|
Acquadro, C
|
|
1999
|
2 |
5 |
p. 371-
1 p.
|
artikel
|
Tijdschrift beschrijving